{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T18:04:19Z","timestamp":1792260259093,"version":"4.4.0"},"reference-count":27,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,11,30]],"date-time":"2022-11-30T00:00:00Z","timestamp":1669766400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,11,30]],"date-time":"2022-11-30T00:00:00Z","timestamp":1669766400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100006483","name":"AbbVie","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006483","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100005564","name":"Gilead Sciences","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005564","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Addict Sci Clin Pract"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>People who use drugs (PWUD) are at high risk for hepatitis C virus (HCV) infection and its complications. Given the high prevalence rate of HCV in PWUD, the World Health Organization (WHO) emphasizes PWUD as a target population for HCV elimination. The introduction of pangenotypic direct acting antivirals (DAAs) greatly simplifies HCV treatment, which encourages integration of HCV treatment in primary care. Facilitating low threshold HCV care for PWUD by implementing decentralized models is crucial for HCV elimination.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Aims<\/jats:title>\n                <jats:p>With this study we aim to (1) eliminate 90% of identified HCV infections in Dutch addiction care, using a decentralized PWUD-HCV care model, and (2) identify facilitators and barriers for successful implementation of the model using interviews.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>We will perform a multicenter mixed-method study on HCV treatment in addiction care. In a prospective observational study we will examine HCV-related outcomes in PWUD receiving HCV treatment as part of addiction care. The primary outcome is viral elimination, defined as percentage of identified HCV positive patients cured with DAAs. In parallel, we will perform a qualitative study to explore facilitators and barriers for implementation of fully decentralized HCV-PWUD care. We will interview addiction care professionals and board members about their experience with HCV-care as part of addiction care.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Discussion<\/jats:title>\n                <jats:p>This study will show effectiveness of integration of HCV care within addiction care, and provide insight in facilitators and barriers to implement integrated HCV-addiction care. The results will provide recommendations for implementation and maintenance of the decentralized HCV pathway, which can facilitate scaling-up to contribute to reaching WHO HCV elimination goals.<\/jats:p>\n                <jats:p><jats:italic>Trial registration<\/jats:italic> NCT05401136.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s13722-022-00350-1","type":"journal-article","created":{"date-parts":[[2022,11,30]],"date-time":"2022-11-30T08:04:50Z","timestamp":1669795490000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Implementation of a decentralized hepatitis C care pathway for people who use drugs in Dutch addiction care. Study protocol for the Hepatitis C: chain of addiction care (CAC) project"],"prefix":"10.1186","volume":"17","clinical-trial-number":[{"clinical-trial-number":"nct05401136","registry":"10.18810\/clinical-trials-gov"}],"author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4567-2391","authenticated-orcid":false,"given":"Daan W.","family":"Von den Hoff","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Floor A. C.","family":"Berden","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joost P. H.","family":"Drenth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arnt F. A.","family":"Schellekens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"HepNed, NISPA","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,11,30]]},"reference":[{"key":"350_CR1","volume-title":"Combating hepatitis B and C to reach elimination by 2030","author":"WHO","year":"2016","unstructured":"WHO. Combating hepatitis B and C to reach elimination by 2030. Geneva: WHO; 2016."},{"issue":"10207","key":"350_CR2","doi-asserted-by":"publisher","first-page":"1451","DOI":"10.1016\/S0140-6736(19)32320-7","volume":"394","author":"CW Spearman","year":"2019","unstructured":"Spearman CW, et al. Hepatitis C. The Lancet. 2019;394(10207):1451\u201366.","journal-title":"The Lancet"},{"issue":"3","key":"350_CR3","doi-asserted-by":"publisher","first-page":"456","DOI":"10.1111\/liv.14779","volume":"41","author":"I Gamkrelidze","year":"2021","unstructured":"Gamkrelidze I, et al. Progress towards hepatitis C virus elimination in high-income countries: an updated analysis. Liver Int. 2021;41(3):456\u201363.","journal-title":"Liver Int"},{"issue":"19","key":"350_CR4","doi-asserted-by":"publisher","first-page":"4562","DOI":"10.3390\/jcm10194562","volume":"10","author":"M van Dijk","year":"2021","unstructured":"van Dijk M, et al. The Netherlands is on track to meet the World health organization hepatitis C elimination targets by 2030. J Clin Med. 2021;10(19):4562.","journal-title":"J Clin Med"},{"key":"350_CR5","doi-asserted-by":"publisher","first-page":"e147","DOI":"10.1017\/S0950268819000359","volume":"147","author":"J Koopsen","year":"2019","unstructured":"Koopsen J, et al. Chronic hepatitis B and C infections in the Netherlands: estimated prevalence in risk groups and the general population. Epidemiol Infect. 2019;147:e147.","journal-title":"Epidemiol Infect"},{"issue":"Suppl 1","key":"350_CR6","doi-asserted-by":"publisher","first-page":"S19","DOI":"10.1093\/infdis\/jis928","volume":"207","author":"J Grebely","year":"2013","unstructured":"Grebely J, et al. Breaking down the barriers to hepatitis C virus (HCV) treatment among individuals with HCV\/HIV coinfection: action required at the system, provider, and patient levels. J Infect Dis. 2013;207(Suppl 1):S19-25.","journal-title":"J Infect Dis"},{"issue":"12","key":"350_CR7","doi-asserted-by":"publisher","first-page":"1270","DOI":"10.1111\/jvh.13399","volume":"27","author":"M van Dijk","year":"2020","unstructured":"van Dijk M, Drenth JPH, HepNed study. Loss to follow-up in the hepatitis C care cascade: a substantial problem but opportunity for micro-elimination. J Viral Hepat. 2020;27(12):1270\u201383.","journal-title":"J Viral Hepat"},{"issue":"1","key":"350_CR8","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1186\/s12954-019-0316-4","volume":"16","author":"PAM Kracht","year":"2019","unstructured":"Kracht PAM, et al. Introducing hepatitis C virus healthcare pathways in addiction care in the Netherlands with a breakthrough project: a mixed method study. Harm Reduct J. 2019;16(1):45.","journal-title":"Harm Reduct J"},{"issue":"2","key":"350_CR9","doi-asserted-by":"publisher","first-page":"686","DOI":"10.1002\/hep.31060","volume":"71","author":"MG Ghany","year":"2020","unstructured":"Ghany MG, Morgan TR, AIHCG Panel. Hepatitis C guidance 2019 update: American association for the study of liver diseases-infectious diseases society of America recommendations for testing, managing, and treating hepatitis C virus infection. Hepatology. 2020;71(2):686\u2013721.","journal-title":"Hepatology"},{"issue":"5","key":"350_CR10","doi-asserted-by":"publisher","first-page":"1170","DOI":"10.1016\/j.jhep.2020.08.018","volume":"73","author":"European Association for the study of the Liver","year":"2020","unstructured":"European Association for the study of the Liver. EASL recommendations on treatment of hepatitis C: Final update of the series. J Hepatol. 2020;73(5):1170\u2013218.","journal-title":"J Hepatol"},{"issue":"4","key":"350_CR11","doi-asserted-by":"publisher","first-page":"e431","DOI":"10.1016\/S2214-109X(20)30505-2","volume":"9","author":"E Oru","year":"2021","unstructured":"Oru E, et al. Decentralisation, integration, and task-shifting in hepatitis C virus infection testing and treatment: a global systematic review and meta-analysis. Lancet Glob Health. 2021;9(4):e431\u201345.","journal-title":"Lancet Glob Health"},{"key":"350_CR12","doi-asserted-by":"publisher","DOI":"10.1002\/ueg2.12167","author":"DW Von den Hoff","year":"2021","unstructured":"Von den Hoff DW, Berden FAC, Schellekens AFA. If the mountain won\u2019t come to Mohammed, then Mohammed must go to the mountain: Decentralisation of hepatitis C care for people who use drugs. United European Gastroenterol J. 2021. https:\/\/doi.org\/10.1002\/ueg2.12167.","journal-title":"United European Gastroenterol J"},{"issue":"10","key":"350_CR13","doi-asserted-by":"publisher","first-page":"1109","DOI":"10.1002\/ueg2.12156","volume":"9","author":"A Mangia","year":"2021","unstructured":"Mangia A, et al. Increased Hepatitis C virus screening, diagnosis and linkage to care rates among people who use drugs through a patient-centered program from Italy. United Eur Gastroenterol J. 2021;9(10):1109\u201318.","journal-title":"United Eur Gastroenterol J"},{"key":"350_CR14","doi-asserted-by":"publisher","first-page":"108526","DOI":"10.1016\/j.drugalcdep.2021.108526","volume":"220","author":"SA Assoumou","year":"2021","unstructured":"Assoumou SA, et al. Patients at a drug detoxification center share perspectives on how to increase hepatitis C treatment uptake: a qualitative study. Drug Alcohol Depend. 2021;220:108526.","journal-title":"Drug Alcohol Depend"},{"issue":"9","key":"350_CR15","doi-asserted-by":"publisher","first-page":"1094","DOI":"10.1111\/jvh.13119","volume":"26","author":"AH Litwin","year":"2019","unstructured":"Litwin AH, et al. Perceived barriers related to testing, management and treatment of HCV infection among physicians prescribing opioid agonist therapy: the C-SCOPE study. J Viral Hepat. 2019;26(9):1094\u2013104.","journal-title":"J Viral Hepat"},{"issue":"2","key":"350_CR16","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1111\/jvh.13214","volume":"27","author":"C Phillips","year":"2020","unstructured":"Phillips C, et al. Improving access to care for people who inject drugs: qualitative evaluation of project ITTREAT-an integrated community hepatitis C service. J Viral Hepat. 2020;27(2):176\u201387.","journal-title":"J Viral Hepat"},{"issue":"1","key":"350_CR17","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1186\/s13722-021-00260-8","volume":"16","author":"JI Tsui","year":"2021","unstructured":"Tsui JI, et al. \u201cTreat my whole person, not just my condition\u201d: qualitative explorations of hepatitis C care delivery preferences among people who inject drugs. Addict Sci Clin Pract. 2021;16(1):52.","journal-title":"Addict Sci Clin Pract"},{"key":"350_CR18","doi-asserted-by":"publisher","first-page":"107705","DOI":"10.1016\/j.drugalcdep.2019.107705","volume":"206","author":"AD Marshall","year":"2020","unstructured":"Marshall AD, et al. Barriers and facilitators to engaging in hepatitis C management and DAA therapy among general practitioners and drug and alcohol specialists-The practitioner experience. Drug Alcohol Depend. 2020;206:107705.","journal-title":"Drug Alcohol Depend"},{"key":"350_CR19","doi-asserted-by":"publisher","DOI":"10.2139\/ssrn.1908913","author":"E Schatz","year":"2011","unstructured":"Schatz E. IDPC Briefing Paper The Dutch treatment and social support system for drug users. Int Drug Policy Consort. 2011. https:\/\/doi.org\/10.2139\/ssrn.1908913.","journal-title":"Int Drug Policy Consort"},{"key":"350_CR20","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1186\/1748-5908-9-74","volume":"9","author":"SN Sweet","year":"2014","unstructured":"Sweet SN, et al. Operationalizing the RE-AIM framework to evaluate the impact of multi-sector partnerships. Implement Sci. 2014;9:74.","journal-title":"Implement Sci"},{"key":"350_CR21","doi-asserted-by":"publisher","first-page":"64","DOI":"10.3389\/fpubh.2019.00064","volume":"7","author":"RE Glasgow","year":"2019","unstructured":"Glasgow RE, et al. RE-aim planning and evaluation framework: adapting to new science and practice with a 20-year review. Front Public Health. 2019;7:64.","journal-title":"Front Public Health"},{"key":"350_CR22","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejim.2022.04.024","author":"CJ Isfordink","year":"2022","unstructured":"Isfordink CJ, et al. Hepatitis C Elimination in the Netherlands (CELINE): how nationwide retrieval of lost to follow-up hepatitis C patients contributes to micro-elimination. Eur J Intern Med. 2022. https:\/\/doi.org\/10.1016\/j.ejim.2022.04.024.","journal-title":"Eur J Intern Med"},{"key":"350_CR23","unstructured":"Federation of Dutch Medical Scientific Societies; The code of conduct for the use of data in health research. 2004."},{"issue":"2","key":"350_CR24","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1191\/1478088706qp063oa","volume":"3","author":"V Braun","year":"2006","unstructured":"Braun V, Clarke V. Using thematic analysis in psychology. Qual Res Psychol. 2006;3(2):77\u2013101.","journal-title":"Qual Res Psychol"},{"key":"350_CR25","volume-title":"Report WHO Global health sector strategy on viral hepatitis","author":"WH Organization","year":"2017","unstructured":"Organization WH. Report WHO Global health sector strategy on viral hepatitis. Geneva: WHO; 2017."},{"key":"350_CR26","unstructured":"Cruts G, V.L.M., Buster M. Aantal en kenmerken van problematische opiatengebruikers in Nederland. Utrecht\/Amsterdam: Trimbos-instituut\/GGD Amsterdam, 2013."},{"key":"350_CR27","unstructured":"Nationale Drug Monitor. Opiaten 5.6 Hulpvraag en incidenten\u2014Nationale Drug Monitor. 2022; https:\/\/www.nationaledrugmonitor.nl\/opiaten-hulpvraag-en-incidenten\/. Accessed on 2 Nov 2022."}],"container-title":["Addiction Science &amp; Clinical Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13722-022-00350-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13722-022-00350-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13722-022-00350-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,11,30]],"date-time":"2022-11-30T08:13:55Z","timestamp":1669796035000},"score":1,"resource":{"primary":{"URL":"https:\/\/ascpjournal.biomedcentral.com\/articles\/10.1186\/s13722-022-00350-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11,30]]},"references-count":27,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,12]]}},"alternative-id":["350"],"URL":"https:\/\/doi.org\/10.1186\/s13722-022-00350-1","relation":{},"ISSN":["1940-0640"],"issn-type":[{"value":"1940-0640","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,11,30]]},"assertion":[{"value":"9 June 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 November 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 November 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The Research Ethics Committee Arnhem-Nijmegen has waived formal ethical approval for this study, indicating it is not included in the Medical Research Involving Human Subjects Act. Participants will provide written informed consent.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"DV and JD declare receipt of funds from AbbVie and Gilead. All other authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"67"}}